Get started
Author

Matt Hoberman

Observed name: M. Hoberman
OpenAlex ID: A5047440523
564P Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours
2020 · J.S. Wang, M.A. Barve, et al. · Annals of Oncology · 4
Abstract 2929: LX-101, a novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent anti-tumor activity in Ewing sarcoma animal models and desmoplastic small round cell tumor
2025 · Matt Hoberman, Danh Dinh Truong, et al. · Cancer Research
Abstract 2949: LX-101, a novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent preclinical anti-tumor activity against multiple cancer types with elevated IGF-1R expression
2025 · Matt Hoberman · Cancer Research
67P LX-101: A novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent anti-tumor activity in Ewing sarcoma (ES) animal models and desmoplastic small round cell tumor (DSRCT)
2025 · M. Hoberman, D.D. Truong, et al. · ESMO Open
PDF
71P LX-101: A novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent preclinical anti-tumor activity against multiple cancer types with elevated IGF-1R expression
2025 · P. McDonald, M. Hoberman · ESMO Open
Abstract 1918: LX-101, a novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent preclinical anti-tumor activity against multiple cancer types with well-established ties to the IGF-1/IGF-1R pathway
2024 · Matt Hoberman, Arkadiusz Z. Dudek · Cancer Research
105P LX-101, a novel, clinical stage, payload-bearing, IGF-1R targeted therapy, has potent preclinical anti-tumor activity against sarcomas and other IGF-related cancers
2024 · M. Hoberman · ESMO Open
PDF
64P LX-101, a novel, clinical stage, payload-bearing IGF-1R targeted therapy, demonstrates activity in patients with high IGF-1R tumor expression
2024 · A.Z. Dudek, M. Hoberman · ESMO Open
PDF
Works count: 8
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type